1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CorMedix Inc.
  6. News
  7. Summary
    CRMD   US21900C3088

CORMEDIX INC.

(CRMD)
  Report
Delayed Nasdaq  -  04:00 2022-08-05 pm EDT
7.130 USD   +8.85%
08/01CorMedix Inc. To Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11
AQ
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 2500 Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 2000 Dynamic Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

CORMEDIX INC. : Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits (form 8-K)

05/12/2022 | 04:17pm EDT

Item 2.02 Results of Operations and Financial Condition

On May 12, 2022, CorMedix Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2022. A copy of the press release is furnished as Exhibit 99.1 to this report.

A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.


 Item 8.01 Other Events



On May 12, 2022, the Company issued a press release announcing updates to its leadership team and changes to its international operations. A copy of the press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits




(d) Exhibits



Exhibit No.   Description

99.1            Press Release dated May 12, 2022
99.2            Press Release dated May 12, 2022
104           Cover Page Interactive Data File (embedded within the Inline XBRL document)

© Edgar Online, source Glimpses

All news about CORMEDIX INC.
08/01CorMedix Inc. To Report Second Quarter 2022 Financial Results and Provide a Corporate U..
AQ
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 2500 Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 2000 Dynamic Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 3000 Growth Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 2000 Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 2000 Growth Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 2000 Value Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell Small Cap Comp Growth Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 3000 Value Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 3000E Index
CI
More news
Analyst Recommendations on CORMEDIX INC.
More recommendations
Financials (USD)
Sales 2022 0,64 M - -
Net income 2022 -36,5 M - -
Net cash 2022 118 M - -
P/E ratio 2022 -8,20x
Yield 2022 -
Capitalization 279 M 279 M -
EV / Sales 2022 253x
EV / Sales 2023 8,14x
Nbr of Employees 30
Free-Float 98,7%
Chart CORMEDIX INC.
Duration : Period :
CorMedix Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CORMEDIX INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 7,13 $
Average target price 22,00 $
Spread / Average Target 209%
EPS Revisions
Managers and Directors
Joseph Todisco Chief Executive Officer & Director
Mathew T. David Chief Financial Officer & Executive Vice President
Myron Lawrence Kaplan Chairman
Antony E. Pfaffle Secretary & Chief Scientific Officer
Elizabeth Masson-Hurlburt Executive VP-Clinical & Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
CORMEDIX INC.56.70%279
MERCK KGAA-18.70%81 493
KYOWA KIRIN CO. LTD.-0.32%12 405
SK BIOPHARMACEUTICALS CO., LTD.-16.67%4 866
BETTA PHARMACEUTICALS CO., LTD.-33.13%3 279
YUHAN CORPORATION-6.12%3 047